ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "ASCO 2025 Plenary: SERENA-6"
Episode Synopsis
This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer.We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.
More episodes of the podcast Two Onc Docs
Hodgkin Lymphoma 2025 UPDATE
24/11/2025
Anal Cancer 2025 UPDATE
17/11/2025
Urothelial ESMO 2025 Updates
10/11/2025
Board Review Tidbits
03/11/2025
Porphyria
27/10/2025
Metastatic Breast Cancer 2025 UPDATE
20/10/2025
Localized Breast Cancer 2025 UPDATE
13/10/2025
In God we trust